【JP:7079】Stock Price

WDB Coco is a company that provides outsourcing and support services for pharmaceutical development, primarily focused on "safety information management services." The company also offers "document support services," "post-marketing surveillance support services," and "clinical research support services." These services are delivered through outsourcing contracts and staffing arrangements.

The "safety information management service" handles data entry, assessment preparation, and report drafting for safety information related to clinical trials and marketed pharmaceuticals both domestically and internationally. The company collects information on adverse drug reactions and supports reporting to the PMDA (Pharmaceuticals and Medical Devices Agency). The service also includes Japanese-English translation and document filing.

The "document support service" provides quality assurance, translation, and CTD (Common Technical Document) creation support for documents required at each stage of pharmaceutical development and regulatory submission materials to the PMDA. This supports the drug approval application process.

The "post-marketing surveillance support service" offers contract document preparation with medical institutions, survey questionnaire management, data management, statistical analysis, and call center operations for investigations following new drug approval or indication expansion. This enables smooth execution of post-marketing surveillance activities.

The "clinical research support service" provides one-stop support for medical research, including assistance to participating medical institutions, clinical data collection and verification, monitoring, statistical analysis, and results report preparation. This supports efficient research implementation.

WDB Coco addresses challenges faced by pharmaceutical and medical device companies—such as cost reduction and changing profitability—by providing business support services to solve customer issues. The company offers services including "safety information management," "post-market surveillance," "document support," and "clinical research," with the goal of improving quality and productivity.

The company is advancing standardization and automation of business processes to deliver greater value to customers. This strengthens competitive advantage and drives sustainable growth and long-term corporate value enhancement. In particular, the company prioritizes operating profit margin as a key performance metric and focuses on expanding profitability.

In the CRO market, generative AI and automation technologies are transforming how work is conducted. WDB Coco capitalizes on this shift by advancing automation and standardization of business processes while strengthening center operations. By concentrating resources on high-value-added areas, the company is establishing a new CRO model that coexists with AI, addressing customers' fundamental business challenges.